Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care

BMC Cancer

Table 5 Multivariate risk model for disease progression

Factor	HR	95% CI	p-value
Age
50 – 59	2.20	1.15 – 4.21	0.017*
60 – 69	1.40	0.68 – 2.89	0.358
≥ 70	1.68	0.79 – 3.59	0.178
Breslow’s index
1.01 – 2.00 mm	0.93	0.48 – 1.80	0.822
2.01 – 4.00 mm	0.65	0.32 – 1.32	0.229
≥ 4.01 mm	1.43	0.65 – 3.15	0.375
Sex
female	1.03	0.61 – 1.72	0.921
Histologic subtype
nodular type	1.29	0.75 – 2.22	0.361
Mutational status
BRAF	0.75	0.39 – 1.46	0.388
NRAS	2.01	1.02 – 3.98	0.045*
SLNB
positive	0.95	0.51 – 1.79	0.877

Multivariate model for disease progression where death was considered a competing risk (competing risk model). The references for each factor were age < 50 years, Breslow’s thickness < 1.00 mm, male sex, non-nodular histologic subtype, WT for BRAF and NRAS, and negative SLNB status. Hazard ratios (HR) for progression and 95% confidence intervals (CI) are indicated; SLNB sentinel lymph node biopsy, ICB immune checkpoint blockade; *p < 0.05

ISSN: 1471-2407